Rayence Co

Rayence Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Rayence Co (228850.KQ) as of Nov 7, 2026 is 25.39 %. In the previous year, CapEx to Operating Cash Flow Ratio was 33.67 % — a change of -24.58% (lower).

CapEx/OCF

25.39 %

YoY

-24.58%

Last updated:

CapEx to Operating Cash Flow Ratio of Rayence Co is 2025 25.39 % . CapEx to Operating Cash Flow Ratio of Rayence Co was 2024 33.67 % . It decreases by -24.58% lower compared to the previous year.

The Rayence Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
17.63 KRW
Jan 1, 2019
76.00 KRW
Jan 1, 2020
10.72 KRW
Jan 1, 2021
9.12 KRW
Jan 1, 2022
11.51 KRW
Jan 1, 2023
16.81 KRW
Jan 1, 2024
33.67 KRW
Jan 1, 2025
25.39 KRW
The Rayence Co CapEx/OCF history
YEARCapEx/OCFYoY
25.39 %-24.58%
33.67 %+100.24%
16.81 %+46.09%
11.51 %+26.15%
9.12 %-14.86%
10.72 %-85.90%
76.00 %+331.12%
17.63 %-25.26%
23.59 %-87.06%
182.33 %+66.53%
109.49 %+8.63%
100.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

CapEx to Operating Cash Flow Ratio of Rayence Co is 25.39 % in 2025.

CapEx to Operating Cash Flow Ratio of Rayence Co changed from 33.67 % to 25.39 %, representing a -24.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Rayence Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Rayence Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Rayence Co

All Key Metrics — Rayence Co